The PI3K signaling pathway is one of the most frequently activated communication networks inside human cells, governing decisions about growth, metabolism, survival, and movement. First identified roughly thirty years ago as a lipid-modifying enzyme associated with cancer-promoting proteins, PI3K (phosphoinositide 3-kinase) has since become a central focus in drug development for cancer, immune disorders, and metabolic disease.1PubMed. PIK3CA in cancer: The past 30 years Understanding how this pathway works, what keeps it in check, and what happens when it misfires helps explain a surprising number of diseases and the drugs designed to treat them.
What PI3K Actually Does
At its core, PI3K is a lipid kinase, meaning it modifies fats rather than proteins. Specifically, it takes a membrane lipid called PIP2 and adds a phosphate group to it, producing a second lipid called PIP3.2Biophysical Journal. Mechanism of Synergistic Activation of Class IA Phosphoinositide 3-Kinase α by Receptor Phospho-Tyr and Membrane-Anchored H-Ras – Section: Results That PIP3 molecule, sitting on the inner surface of the cell membrane, acts as a docking signal. Proteins that recognize PIP3 get recruited to the membrane and switched on, triggering cascades that tell the cell to grow, divide, take up nutrients, or resist programmed death. The pathway activates when an outside signal, such as a growth factor or insulin, binds to a receptor on the cell surface. That receptor either directly recruits PI3K or activates intermediary proteins that do.
Three Classes of PI3K
PI3K is not a single enzyme but a family divided into three classes (I, II, and III), each with its own structure and biological job. Researchers increasingly recognize that these classes, and the individual members within them, have distinct and sometimes non-overlapping functions.3PubMed Central. Classes of phosphoinositide 3-kinases at a glance Class I PI3K is the most studied. It sits downstream of growth factor receptors and is the version most commonly mutated in cancer. It comes in four catalytic flavors, called p110α, p110β, p110γ, and p110δ, each encoded by a different gene. The α and β forms are found in virtually all tissues, while γ and δ are concentrated in immune cells, a distinction that has driven the development of immune-targeted drugs.
Class II PI3Ks are less well understood but appear to play roles in membrane trafficking and vascular integrity. Class III PI3K, known as Vps34, has a completely different job description: it is essential for autophagy, the process by which cells digest their own damaged components for recycling, and for the trafficking of material taken in from outside the cell.4PubMed Central. Class III PI3K Vps34: essential roles in autophagy, endocytosis, and heart and liver function This means the PI3K family simultaneously controls growth-promoting signals (Class I) and cellular housekeeping (Class III), two activities that can work at cross purposes depending on the cell’s circumstances.
PTEN, the Pathway’s Off Switch
Because PI3K signaling is so powerful, the cell needs an equally powerful brake. That brake is PTEN, a phosphatase enzyme that does the exact opposite of PI3K: it strips the phosphate group off PIP3, converting it back to PIP2 and shutting the signal down.5iScience. The mechanism of full activation of tumor suppressor PTEN at the phosphoinositide-enriched membrane – Section: Summary PTEN is the second most frequently mutated gene in human cancers, right behind p53.6iScience. The mechanism of full activation of tumor suppressor PTEN at the phosphoinositide-enriched membrane – Section: Summary When PTEN is lost or damaged, PIP3 accumulates on cell membranes, and the growth and survival signals downstream never turn off.
The relationship between PI3K and PTEN is not a simple seesaw. Cancer cells have evolved multiple ways to tip the balance in favor of PIP3 accumulation even when PTEN is partially intact, including altering other enzymes that regulate the same lipids and using regulatory molecules that dampen PTEN’s activity without eliminating it entirely.7PubMed Central. PTEN Tumor Suppressor Network in PI3K-Akt Pathway Control PIP3 itself is a key regulator of cell proliferation, survival, and migration, so even modest shifts in its abundance can have large biological consequences.8PubMed Central. Engineering ePTEN, an enhanced PTEN with increased tumor suppressor activities
What Happens Downstream of PIP3
Once PIP3 appears on the membrane, it recruits a protein called Akt (also known as protein kinase B). Akt binds PIP3, which pulls it to the membrane surface where another enzyme called PDK1 can phosphorylate and activate it.9PubMed. The deacetylase SIRT1 promotes membrane localization and activation of Akt and PDK1 during tumorigenesis and cardiac hypertrophy Activated Akt then fans out across the cell, adding phosphate groups to dozens of different target proteins. The effect depends on the target: some get turned on, others get turned off. The net result is a coordinated push toward cell growth, survival, and nutrient uptake.
One of Akt’s most consequential targets is a protein complex called mTORC1, a master regulator of cell growth. Akt does not activate mTORC1 directly. Instead, it phosphorylates a protein called TSC2, which normally acts as a brake on mTORC1. When Akt inactivates TSC2, that brake is released, and mTORC1 becomes active.10PLoS ONE. Insulin Stimulates Adipogenesis through the Akt-TSC2-mTORC1 Pathway – Section: Results Active mTORC1 drives protein synthesis, lipid production, and energy metabolism, the building blocks a growing cell needs. This PI3K→Akt→mTOR chain is one of the most commonly hijacked routes in cancer, and it explains why so many cancer drugs target different steps along the same chain.
The Metabolic Side of PI3K Signaling
The pathway’s connection to metabolism runs deep because PI3K is one of the primary mediators of insulin action. When insulin binds its receptor, the resulting PI3K activation leads to Akt turning on, which triggers the movement of glucose transporters called GLUT4 from storage compartments inside the cell to the cell surface. Once GLUT4 is on the surface, the cell can absorb glucose from the bloodstream.11IntechOpen. Role of PI3K/AKT Pathway in Insulin-Mediated Glucose Uptake – Section: 3. PI3K/AKT pathway The same Akt activity also promotes glycogen synthesis, the process by which the liver and muscles store glucose for later use, by inactivating an enzyme called GSK3.12IntechOpen. Role of PI3K/AKT Pathway in Insulin-Mediated Glucose Uptake – Section: 3. PI3K/AKT pathway
In fat cells, PI3K/Akt signaling enhances glucose uptake through GLUT4, promotes the creation of new fat molecules, and slows down fat breakdown.13Biomedicine & Pharmacotherapy. Targeting PI3K/AKT signaling pathway in obesity – Section: 2.1. Role of PI3K/AKT in adipose tissue This dual role in both muscle and fat tissue makes the pathway a natural point of interest for researchers studying obesity and type 2 diabetes. The metabolic connection also creates practical problems for cancer treatment, as we’ll see shortly.
One wrinkle worth noting: the relationship between PI3K/Akt activity and glucose uptake is not always straightforward. In heart muscle cells, constitutive (always-on) activation of PI3K and Akt actually impairs glucose uptake, even though GLUT4 still reaches the cell surface normally. Something about chronically elevated signaling appears to damage GLUT4’s ability to function after it gets inserted into the membrane.14PubMed Central. Cardiac PI3K-Akt impairs insulin-stimulated glucose uptake independent of mTORC1 and GLUT4 translocation This is a reminder that “more signaling” does not always mean “more benefit,” and that the same pathway can behave differently depending on which tissue you are looking at and how long the signal persists.
PI3K in the Immune System
Two class I PI3K isoforms, p110γ and p110δ, are concentrated in white blood cells, and their roles in immunity are distinct enough that they have become drug targets in their own right. PI3Kγ is particularly important for the recruitment of innate immune cells to sites of infection or injury, driven by chemical signals called chemokines. PI3Kδ, on the other hand, plays a central role in the development and function of B cells and T cells, the adaptive arm of the immune system.15PubMed. PI3K signalling in inflammation
Because these two isoforms have non-overlapping jobs in immune cell signaling, drugs that block one or both can modulate the immune response in useful ways. Blocking PI3Kδ interferes with B cell and T cell activation, which is helpful in cancers of the blood system and potentially in autoimmune diseases. Blocking PI3Kγ dials down the inflammatory cell response. A dual inhibitor targeting both isoforms has shown efficacy against immune-driven disorders in preclinical testing.16Chemistry & Biology. IPI-145, a Potent Inhibitor of PI3K-δ and PI3K-γ, Prevents Immune Cell Responses and Ameliorates Autoimmune Disease in Animal Models – Section: Significance The fact that these isoforms are largely restricted to white blood cells offers a therapeutic advantage: drugs targeting them can modulate immunity without heavily disrupting the PI3K signaling that every other tissue depends on.
Why PI3K Matters So Much in Cancer
The gene encoding p110α, called PIK3CA, is one of the most frequently mutated genes across all human cancers. Mutations in PIK3CA make the kinase overly active, flooding the cell with PIP3 and cranking up growth signals even without an external growth factor telling the cell to divide. In breast cancer, roughly 12 to 15 percent of tumors carry not just one but two PIK3CA mutations on the same copy of the gene, a double-hit arrangement that further ramps up PI3K activity and downstream signaling.17PubMed Central. Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors These double mutations work biochemically by increasing the disruption of p110α’s binding to its regulatory partner p85α. Under normal conditions, p85 holds p110α in an inactive state. When both mutation sites cooperate, the inhibitory grip loosens further, leaving the kinase essentially unleashed.18PubMed Central. Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors
Combined with PTEN loss described above, activating PIK3CA mutations create a two-pronged problem: the gas pedal gets stuck and the brake line gets cut. This is why the PI3K pathway is altered in an unusually broad range of tumor types, not just breast cancer but also endometrial, colorectal, ovarian, and brain cancers, among others.
PI3K Inhibitors and the Drug Resistance Problem
Several PI3K inhibitors have reached patients. Drugs like idelalisib, copanlisib, alpelisib, and duvelisib have received FDA approval, primarily for certain blood cancers and PIK3CA-mutated breast cancer.19PubMed. Targeting PI3K in cancer treatment: A comprehensive review with insights from clinical outcomes They come in several flavors: pan-PI3K inhibitors that block all class I isoforms, isoform-selective inhibitors that target just one (like alpelisib, which hits p110α), and dual PI3K/mTOR inhibitors that attack both nodes of the signaling chain simultaneously.
Despite this arsenal, the overall clinical track record has been mixed. A substantial number of patients eventually develop resistance, often because blocking PI3K forces the tumor to activate alternative signaling pathways that bypass the blockade entirely.20PubMed. Targeting PI3K in cancer treatment: A comprehensive review with insights from clinical outcomes The PI3K/Akt/mTOR pathway and another major growth pathway called RAF/MEK/ERK talk to each other extensively. When one is shut down, the other often ramps up to compensate. In melanoma cells resistant to BRAF inhibitors, researchers found strong cross-resistance to PI3K/mTOR inhibitors as well, and the most effective strategy was blocking both pathways at once.21PubMed Central. Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade Similar results have been seen in bile duct cancer, where targeting only one of these two redundant pathways was likely to result in therapy failure.22PubMed. Dual Inhibition of PI3K-AKT-mTOR- and RAF-MEK-ERK-signaling is synergistic in cholangiocarcinoma and reverses acquired resistance to MEK-inhibitors
The Hyperglycemia Catch-22
One of the most clinically frustrating side effects of PI3K inhibitors is high blood sugar. Because PI3Kα is one of the key enzymes insulin depends on to drive glucose into cells, blocking it in a tumor simultaneously disrupts insulin signaling throughout the body. The result is decreased glucose transport, increased breakdown of stored glycogen, and increased production of new glucose by the liver, all of which push blood sugar up.23PubMed Central. Management of Phosphatidylinositol-3-Kinase Inhibitor-Associated Hyperglycemia This hyperglycemia is not just an uncomfortable side effect. The body responds to rising blood sugar by releasing more insulin, and that extra insulin can actually reactivate the PI3K pathway in tumor cells, partly undoing the drug’s anticancer effect.24PubMed Central. Management of Phosphatidylinositol-3-Kinase Inhibitor-Associated Hyperglycemia Hyperglycemia is intrinsically linked to inhibition of PI3Kα because that isoform is a key mediator of insulin signaling, making it difficult to block the enzyme in a tumor without provoking the metabolic rebound.25PubMed. Mechanistic basis for PI3K inhibitor antitumor activity and adverse reactions in advanced breast cancer – Section: RESULTS
Managing this side effect has become a clinical research area in its own right. Dietary strategies, glucose-lowering drugs, and even ketogenic diets are being explored to prevent the insulin surge that undermines treatment. The paradox here captures the core challenge of PI3K-targeted therapy: the pathway is so deeply embedded in normal physiology that shutting it down in one place creates ripple effects everywhere else.
PI3K in the Brain
The two ubiquitous class I isoforms, p110α and p110β, turn out to have surprisingly specialized roles in the nervous system. Research in mouse models has shown that dendritic branching and the structures of synapses on the receiving end of neural connections depend almost entirely on p110α. Neurotransmitter release from the sending side, along with a specific form of synaptic weakening involved in learning and memory, depends on p110β. Both isoforms cooperate in a form of synaptic strengthening tied to memory consolidation.26PubMed Central. Functional specialization of different PI3K isoforms for the control of neuronal architecture, synaptic plasticity, and cognition This functional separation is striking because p110α and p110β generate the same lipid product, PIP3. What differs is where and when each isoform is active within the neuron, which determines which downstream events follow. The finding has implications for understanding how mutations in PI3K pathway genes contribute to intellectual disability and autism spectrum conditions, both of which have been linked to altered PI3K/mTOR signaling in brain development.
The Heart Connection
The PI3K/Akt pathway plays a complex role in the heart. It regulates the size and survival of heart muscle cells, angiogenesis (formation of new blood vessels), and inflammatory responses after injury.27PubMed Central. Interplay between PI3K/AKT pathway and heart disorders When the heart grows larger in response to exercise, PI3K signaling mediates that healthy form of enlargement. But the same pathway is also involved in pathological heart growth, the kind triggered by high blood pressure or valve disease, and in the damage that occurs when blood flow is restored after a heart attack.
Studies using genetically modified mice have helped untangle these roles, demonstrating that the PI3K-Akt axis participates in both physiological and disease-related cardiac hypertrophy.28PubMed Central. Phosphoinositide-3 kinase signaling in cardiac hypertrophy and heart failure This duality means that therapies targeting PI3K must account for potential cardiac effects, particularly in patients with pre-existing heart conditions. The finding from heart muscle cells that constitutive PI3K/Akt activation actually impairs glucose uptake, mentioned earlier, underscores how context-dependent the pathway’s effects can be in cardiac tissue.
Autophagy and Cellular Recycling
While class I PI3K promotes cell growth, class III PI3K (Vps34) has an entirely different mandate. Vps34 generates a lipid called PI3P, which is essential for autophagy, the process cells use to break down and recycle their own damaged proteins and worn-out organelles. In fruit flies engineered to lack Vps34, autophagosome formation was completely disrupted in fat body cells.29PubMed Central. The class III PI(3)K Vps34 promotes autophagy and endocytosis but not TOR signaling in Drosophila In mice, deleting Vps34 blocked both autophagy triggered by nutrient starvation and the normal processing of material taken in from outside the cell.30PubMed Central. Class III PI3K Vps34 plays an essential role in autophagy and in heart and liver function
This creates an interesting tension in cancer biology. Autophagy can either help or hinder tumors depending on the stage. In early cancer development, autophagy suppresses tumor growth by clearing damaged proteins and preventing genomic instability. In established tumors, autophagy can help cancer cells survive stressful conditions like nutrient deprivation or chemotherapy. Drugs that affect different PI3K classes could therefore push autophagy in opposite directions, and understanding which class is being targeted matters for predicting the outcome.
A Scaffolding Surprise
Not everything PI3K-related proteins do involves their enzyme activity. The regulatory subunit p85α, which normally binds and restrains the p110 catalytic subunit, turns out to moonlight as a structural scaffold during cell division. When researchers deleted p85α from cells, those cells had trouble completing the final stage of division, the physical splitting into two daughter cells, and accumulated with two nuclei instead of one. Blocking PI3K’s enzymatic activity with chemical inhibitors did not cause the same problem. The defect was rescued by putting back a version of p85 that cannot even bind the catalytic subunit, confirming that the scaffolding role is independent of PI3K’s lipid kinase function.31PubMed Central. A PI3K activity-independent function of p85 regulatory subunit in control of mammalian cytokinesis What p85 does in this context is organize two other proteins, Cdc42 and septin 2, that are needed for the cell to physically pinch apart. This is a useful reminder that signaling proteins often have structural jobs the cell depends on, and that drug effects on a protein may extend beyond blocking its enzyme activity.
Longevity Clues from Worms
Some of the most dramatic evidence for PI3K’s influence on whole-organism physiology comes from the roundworm C. elegans. Worms carrying mutations that knock out the catalytic subunit of their class I PI3K live far longer than normal and show extraordinary resistance to stress. These effects require the downstream transcription factor DAF-16 (the worm equivalent of the FOXO proteins in humans), confirming that reduced PI3K signaling works through the same pathway logic seen in mammals.32PubMed Central. Caenorhabditis elegans PI3K mutants reveal novel genes underlying exceptional stress resistance and lifespan – Section: Results Gene expression analysis of these long-lived worms found that the overwhelming majority of transcript changes were genes being turned down rather than up, suggesting that the longevity benefit comes from reducing a broad swath of growth-related gene activity.33PubMed Central. Caenorhabditis elegans PI3K mutants reveal novel genes underlying exceptional stress resistance and lifespan – Section: Results
Whether this translates to human aging is an open question. Caloric restriction, which extends lifespan in many organisms, is known to reduce insulin and PI3K/Akt signaling. And the fact that PI3K inhibitors are already being used clinically in cancer patients means there is, in theory, a population in which long-term effects on aging-related biology could eventually be observed, though that is a far cry from calling PI3K inhibitors a longevity drug. What the worm data does show is that PI3K is not just a cancer gene or a metabolism gene. It sits at a fundamental crossroads that influences how aggressively an organism invests in growth versus maintenance and repair.